Osimertinib plus antibody treatment for EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 study tests the combination of osimertinib (a targeted lung cancer pill) with an antibody called carotuximab to treat advanced EGFR-mutated non-small cell lung cancer. It aims to see whether adding the antibody can help when the cancer has grown despite prior EGFR-targeted therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IV) or recurrent/metastatic non-squamous lung cancer with an EGFR activating mutation (like exon 19 deletion or exon 21 L858R).
- Your cancer has grown after prior EGFR pill therapy (and the exact timing depends on which part of the study you enter).
- You are age 18 or older, and your general health is good enough for treatment (ECOG performance status 0 to 2).
- You can provide tumor tissue from after your most recent progression (or you agree to a new biopsy).
- You can start study drugs only after prior chemotherapy or radiation has been fully out of your system for a minimum time (about 3 weeks for chemo, 2 weeks for radiation).
- You do not have certain lung or heart conditions that increase risk (especially active lung scarring/interstitial lung disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
This trial tests if adding sacituzumab tirumotecan to osimertinib works better than osimertinib alone for advanced lung cancer that still shows cancer DNA (ctDNA) in the blood after initial osimertinib treatment.
This Phase 2 study tests a treatment sequence starting with osimertinib, then using chemotherapy after it. It is meant for people with EGFR-mutated advanced lung cancer whose disease has come back or progressed, including a “rechallenge” attempt with osimertinib.
This trial tests combining a targeted pill (EGFR-TKI) with an antibody drug (bevacizumab) for people with advanced non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if this combination works better than the pill alone as a first treatment.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.